153 related articles for article (PubMed ID: 35735429)
1. Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid Cancer.
Baumgarten J; Happel C; Groener D; Staudt J; Bockisch B; Sabet A; Grünwald F; Rink T
Curr Oncol; 2022 May; 29(6):4012-4019. PubMed ID: 35735429
[TBL] [Abstract][Full Text] [Related]
2. Serum thyroglobulin in thyroid carcinoma and other thyroid disorders.
Pacini F; Pinchera A; Giani C; Grasso L; Doveri F; Baschieri L
J Endocrinol Invest; 1980; 3(3):283-92. PubMed ID: 7430557
[TBL] [Abstract][Full Text] [Related]
3. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas.
Herle AJ; Uller RP
J Clin Invest; 1975 Aug; 56(2):272-7. PubMed ID: 1150869
[TBL] [Abstract][Full Text] [Related]
5. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
[TBL] [Abstract][Full Text] [Related]
6. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
[TBL] [Abstract][Full Text] [Related]
7. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
8. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
[TBL] [Abstract][Full Text] [Related]
10. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
[TBL] [Abstract][Full Text] [Related]
11. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma.
Özdoğan Ö; Aksu A; Doğan E; Bülbül O; Güray Durak M; Sevinç Aİ; Bayraktar F; İkiz AÖ
Ann Nucl Med; 2021 Feb; 35(2):223-231. PubMed ID: 33389664
[TBL] [Abstract][Full Text] [Related]
12. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
Podoba J
Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310
[TBL] [Abstract][Full Text] [Related]
14. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
15. Thyroglobulin levels to follow-up patients with treated differentiated thyroid carcinoma.
Moser E; Braun S; Büell U; Kirsch CM; Tosch U; Wendt T
Cancer Detect Prev; 1984; 7(2):79-86. PubMed ID: 6424939
[TBL] [Abstract][Full Text] [Related]
16. Serum thyroglobulin concentrations and 131I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy).
Pacini F; Pinchera A; Giani C; Grasso L; Baschieri L
Clin Endocrinol (Oxf); 1980 Jul; 13(1):107-10. PubMed ID: 7438460
[TBL] [Abstract][Full Text] [Related]
17. Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors.
Leboeuf R; Emerick LE; Martorella AJ; Tuttle RM
Thyroid; 2007 Jun; 17(6):543-7. PubMed ID: 17614775
[TBL] [Abstract][Full Text] [Related]
18. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy has no significant impact on the prognosis of differentiated thyroid cancer.
Nobre GM; Tramontin MY; Treistman N; Alves PA; Andrade FA; Bulzico DA; Corbo R; Vaisman F
Arch Endocrinol Metab; 2021 Nov; 65(6):768-777. PubMed ID: 34762783
[TBL] [Abstract][Full Text] [Related]
20. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
Schlüter B; Bohuslavizki KH; Beyer W; Plotkin M; Buchert R; Clausen M
J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
